Table 1 Demographic, clinical and biochemical parameters in 198 APAP-ALF patients by outcome
APAP alive day 21 (n = 99) | APAP dead day 21 (n = 99) | p value | |||
|---|---|---|---|---|---|
N | Number (%) or median (IQR) | N | Number (%) or median (IQR) | ||
Age | 99 | 35 (28–43) | 99 | 40 (30–48) | 0.084 |
Sex (female) | 99 | 75 (76%) | 99 | 72 (73%) | 0.63 |
Race | 0.23 | ||||
White | 99 | 83 (84%) | 99 | 79 (80%) | |
African-American | 99 | 8 (8%) | 99 | 15 (15%) | |
Other | 99 | 8 (8%) | 99 | 5 (5%) | |
Organ support (days 1–7) | |||||
Mechanical ventilation | 99 | 64 (65%) | 99 | 93 (93%) | < 0.0001 |
Vasopressors | 99 | 12 (12%) | 99 | 69 (70%) | < 0.0001 |
Renal replacement therapy | 99 | 27 (27%) | 99 | 45 (45%) | 0.0078 |
KCC | 87 | 7 (7%) | 87 | 16 (16%) | 0.13 |
Coma grade 3/4 (worst days 1–7) | 99 | 61 (62%) | 98 | 91 (93%) | < 0.0001 |
ICP-directed therapies (days 1–7) | |||||
ICP monitor | 99 | 12 (12%) | 99 | 21 (21%) | 0.086 |
Mannitol | 99 | 22 (22%) | 99 | 46 (46%) | 0.0003 |
Hypertonic saline | 99 | 11 (11%) | 99 | 14 (14%) | 0.52 |
Barbiturates | 99 | 9 (9%) | 99 | 20 (20%) | 0.043 |
Hypothermia | 99 | 17 (17%) | 99 | 14 (14%) | 0.56 |
Sedatives | 99 | 70 (71%) | 99 | 88 (89%) | 0.0014 |
Blood products (days 1–7) | |||||
Red blood cells | 99 | 34 (34%) | 99 | 50 (51%) | 0.021 |
Fresh-frozen plasma | 99 | 50 (51%) | 99 | 76 (77%) | 0.0001 |
Recombinant VIIA | 99 | 3 (3%) | 99 | 5 (5%) | 0.72 |
Platelets | 99 | 17 (17%) | 99 | 36 (36%) | 0.0023 |
ICU complications (days 1–7) | |||||
Seizures | 99 | 3 (3%) | 99 | 21 (21%) | < 0.0001 |
Arrhythmias | 99 | 25 (25%) | 99 | 38 (38%) | 0.047 |
GI bleeding | 99 | 8 (8%) | 99 | 19 (19%) | 0.037 |
ARDS | 99 | 0 (0%) | 99 | 3 (3%) | 0.25 |
CT (cerebral edema) | 55 | 7 (13%) | 72 | 32 (44%) | < 0.001 |
Abnormal CXR | 99 | 88 (89%) | 99 | 83 (84%) | 0.30 |
Bacteremia/blood stream infection | 99 | 7 (7%) | 99 | 10 (10%) | 0.61 |
Cause of death | |||||
Multiorgan failure | 99 | 52 (53%) | |||
Cerebral edema | 99 | 38 (38%) | |||
Unknown | 99 | 9 (9%) | |||